Psychiatric disorders such as autism spectrum disorders, attention deficit hyperactivity disorder, and schizophrenia often have a strong genetic component. With the advancement of new genetic testing technologies, genetic diagnostics can diagnose the genetic potential of psychiatric disorders and inform prognosis and therapeutic response in a research setting.

Ace Therapeutics is committed to applying our state-of-the-art technology to provide clients with a comprehensive range of genetic diagnostic development services for psychiatric disorders, from the development of diagnostic biomarkers for genetic diagnostics to the design of personalized genetic tests, from the development of genetic diagnostic biomarkers to the design of personalized genetic testing protocols. We use advanced high-throughput sequencing technology combined with professional bioinformatics analysis tools to discover genetic variants associated with mental disorders and provide reliable, high-quality data for accurate diagnosis of mental disorders.

Our Genetic Diagnostic Methods Development Services for Psychiatric Disorders

• Genetic diagnostic biomarker development services

Selecting the right biomarker for the diagnosis of psychiatric disorders is a complex process. Ace Therapeutics is committed to providing advanced technologies and solutions to help customers develop genetic diagnostic biomarkers for psychiatric disorders, covering the following areas:

• We help our clients discover genetic variants, copy number variations, and single nucleotide polymorphisms associated with psychiatric disorders using high-throughput sequencing, bioinformatics analysis, genetics, and molecular biology technologies, and conduct in-depth research and functional validation to determine their specific roles in disease onset and progression.
• We also utilize cellular and animal models to further validate the potential value of these genetic variants as biomarkers.

Through this series of scientific studies and validations, we can provide our clients with comprehensive genetic biomarker development solutions to accelerate innovation and application in the field of genetic diagnostics for psychiatric disorders.

• Genetic test development services for psychiatric disorders

New technologies in genetic testing are valuable in accurately diagnosing psychiatric disorders with high genetic risk. Ace Therapeutics provides genetic test development services for the diagnosis of psychiatric disorders such as autism, attention-deficit hyperactivity disorder (ADHD), and schizophrenia. Our strategy includes:

• Combining genetic testing technologies with a wide range of genetic analyses such as chromosome microarray analysis (CMA), copy number variation (CNV) analysis, (targeted) next-generation sequencing (NGS) and PRS, as well as the latest in genetic biomarker research, to provide accurate diagnostic strategies for high-risk psychiatric disorders.
• Combining genetic testing with neuroimaging, digital phenotyping, and computational modeling provides a comprehensive solution to accurately diagnose psychiatric disorders such as ASD and to clarify the genetic status of psychiatric disorders.

Our Approach

• Genomics research methods: Sequencing and analyzing genomes to discover genetic variants associated with disease.
• Genetic research methods: We use genetic tools to discover patterns of inheritance and genetic variants associated with disease.
• Association studies: We identify genetic variants associated with disease by comparing genomic and genetic information between cases and healthy populations.
• Functional studies: To study the effects of genetic variation on cellular function and biological processes using laboratory and cell biology methods.

Ace Therapeutics is committed to applying our expertise and technology to provide our clients with comprehensive solutions that offer insight into the genetic diagnosis of psychiatric disorders. If you are interested in our services, please contact us and we will be happy to share more details and explore the frontiers of mental health together.

Reference

1. Pinzón E. J.; et al. Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe. Translational psychiatry. 12.1 (2022): 442.